Morning Overview on MSN
AlphaFold rewired science, and 5 years later it’s still evolving
AlphaFold arrived as a technical moonshot that suddenly made protein structures feel like software rather than secrets of ...
Abstract: The extensive adoption of cloud computing platforms in storing and processing data have brought forth a new age of efficiency in the way data is stored, processed and managed, requiring new ...
Abstract: Recently, several approaches have been designed to hide data in portable document format (PDF) files. These approaches have demonstrated their advantages in different application scenarios, ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results